Alpha emitters have always promised to deliver potential benefit in cancer therapy. Using the example of radium-223 (Xofigo) and the paradigm of ionising radiation, this review looks at targeted alpha therapy from the perspective of a radiation oncologist.
Bibliographical notePublisher Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
- prostate cancer
- Targeted alpha therapy
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
- Radiology Nuclear Medicine and imaging